ABD - İngilizce - NLM (National Library of Medicine)

northstar rxllc - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.  paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated

ABD - İngilizce - NLM (National Library of Medicine)

rebel distributors corp - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 6 mg - invega® (paliperidone) extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14)] . monotherapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as monotherapy. adjunctive therapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. invega® (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in invega® . pregnancy category c . there are no adequate and well controlled studies of invega® in pregnant women. invega® should be used during pregnancy only if the potential benefit jus

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

norton waterford - paliperidone - prolonged-release suspension for injection - 100 milligram(s) - paliperidone

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

norton waterford - paliperidone - prolonged-release suspension for injection - 150 milligram(s) - paliperidone

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

norton waterford - paliperidone - prolonged-release suspension for injection - 25 milligram(s) - paliperidone

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

norton waterford - paliperidone - prolonged-release suspension for injection - 50 milligram(s) - paliperidone

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

norton waterford - paliperidone - prolonged-release suspension for injection - 75 milligram(s) - paliperidone

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.